Micronutrients & recovery
Duodenal-jejunal bypass liner (DJBL) therapy causes significant depletion of essential fatty acids (linoleic acid, alpha-linolenic acid) and their long-chain polyunsaturated derivatives (arachidonic, eicosapentaenoic, docosahexaenoic acids) in the blood.
If you undergo DJBL (EndoBarrier) therapy, you are at high risk for depleting essential fatty acids (Omega-3 and Omega-6). This device blocks absorption in the upper small intestine. To mitigate this, you must ensure adequate dietary intake of healthy fats (fish, nuts, seeds) or take high-quality fish oil/PUFA supplements, as standard diets may not be enough to overcome the malabsorption. Monitor your levels with your doctor.
Absolute concentrations of both EFAs, linoleic acid and a-linolenic acid, and their bioactive derivatives, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, were significantly lower in the DJBL group than in the control group at 6 and 11.5 months follow-up.
Why this rating
Randomized controlled trial with a control group, though the primary power was for HbA1c, the fatty acid analysis was a pre-specified secondary outcome with robust statistical modeling.
Source
The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids
Michael A. Glaysher et al. · Clinical Nutrition · 2020
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →